Transforming the Business of Oncology through … the 2017 Summit is Transforming the Business of...

1

Transforming the Business of Oncology through Science and Technology

February 6-7, 2017 • The Aria Resort • Las Vegas, Nevada

CancerBusinessSummit.com

2017 SPONSORSAlliance Oncology • Animated Dynamics • Archway Health • Bayer HealthCare Pharmaceuticals, Inc. • Cancer Treatment Centers of America®

Cardinal Health Specialty Solutions • Carevive Systems, Inc. • ECG Management Consultants • Eisai, Inc. • Flatiron Health • Healthcare Appraisers, Inc. Heron Therapeutics • IntegraConnect • Integrated Healthcare Strategies, a division of Gallagher Benefit Services, Inc. • Janssen Pharmaceutical Companies

LeanTaaS • Lilly Oncology • marketware • McKesson Specialty Health & The US Oncology Network • Navigating Cancer • New Century Health Oncology Management Consultants • Oncology Resource Consultants • Oncology Services International • Oncology Solutions, LLC • Oncology Supply/ION Solutions Pinnacle Healthcare Consulting • PYA • Radiation Business Solutions • Revenue Cycle, Inc. • RX Vantage • Sg2 • Strand Diagnostics • Taiho Oncology, Inc.

TEVA Pharmaceuticals • University of Tennessee Knoxville • Varian Medical Systems • Vector Oncology

SUMMIT HOSTS

Washington Outlook Keynote Address by Bill Frist, M.D. 18th Majority Leader, U.S. Senate (2003-2007)

Innovations that Re-Imagine, Re-Design and Re-Build our System of Cancer Care Delivery into the Value-Based System of the Future

www.CancerBusinessSummit.com 2

WELCOME TO THE 2017 CANCER CENTER

BUSINESS SUMMIT

2


We welcome you to the 2017 Cancer Center Business Summit, and look forward to celebrating with you our 10th anniversary. The theme of the 2017 Summit is Transforming the Business of Oncology through Science and Technology. Enabled by cutting edge technologies and new science, innovative oncology stakeholders are undertaking bold initiatives to re-imagine, re-design and re-build our system of cancer care delivery into the “value-based” system of the future-- focused on delivering care more efficiently, in a more patient centered way, and improving patient outcomes and survival rates.

Advances in genomics, genetics, proteomics, immunotherapy, oral oncolytics and other aspects of personalized/precision medicine are changing the way that providers need to organize their businesses to position for future success. This will involve acquisition of new equipment, software, and information technologies, as well as changes in work flow and staffing requirements. As such, the business and economic models for the cancer centers of the future are evolving and will look quite different from the care delivery models of today.

In addition, changes are afoot in payment models that are driving the transformation to value-based oncology care delivery. For example, CMMI’s Oncology Care Model program (OCM) represents a bold and significant step in the transition to value-based oncology care. There are also other bundled or episode of care payment programs being piloted by health insurers, self-insured plans, and networks of oncology providers. The 2017 Summit will review progress of these payment reform initiatives and lessons learned to date, as well as preview the next generation of payment reforms in oncology. One challenge for all providers involved in oncology alternative payment arrangements will be to determine how to access, analyze, trend and understand massive amounts of clinical and financial/claims data that today are scattered across multiple IT platforms and EMRs. How should providers aggregate, document and report quality measures? How can advanced data analytics serve as the engine of evidence-based change? What care is really more effective and efficient? New technologies and business approaches to address these questions will be explored at the 2017 Summit.

Moreover, the change in Administrations and the rapid pace and magnitude of oncology market changes are breeding uncertainty and creating much anxiety. Oncology providers are concerned about the implications of the anticipated repeal of portions of the Affordable Care Act; about proposed reimbursement changes; about being excluded from narrowing networks; about patient incentives to use less expensive providers and more specialty pharmacies; about losing referral sources as primary care physicians and other specialists align with specific networks; about the pressure to give up practice autonomy and become employees of hospitals, large multi-specialty groups or health systems; about empowered consumers, armed with (mis)information, and turning to self-care options; about funding the infrastructure and administrative costs of patient navigation, care management, population health management, and utilization and health care cost management; about the potential loss or scaling back of site of service differentials and 340B pricing benefits; about misdirected incentives to stint on care, compromise quality and forego more expensive new (and potentially better) technologies and products; and about the trend toward industry consolidation to achieve care coordination and economies of scale, that may threaten clinician independence and self-determination.

In this new health care environment, there are critical questions to be answered about how science and technology will impact oncology business models, and how community oncology stakeholders should be positioning themselves for future success.

At the 2017 Summit, we will examine these issues, and you will have the rare opportunity to learn from industry leaders and from your peers about the changes occurring in the cancer care marketplace and how innovative organizations are responding to them. The Summit faculty consists of experienced cancer care executives, physician leaders, and thought leaders from the financial, business, payor, and legal communities. Their diverse perspectives provide a unique synthesis of the most important issues facing cancer care providers today.

As we begin the 2017 Summit, we give hearty thanks to all of our wonderful faculty members, advisors, and supporters who have given generously of their time, talent, and resources to make this year’s Summit a success. We also thank you for attending and adding your voice to this unique and timely discussion. It is our honor to host you. We hope that you will enjoy the Summit, forge new relationships, and learn practical tips to help build durable, sustainable and successful business models to deliver the oncology care of the future.

Thank you,

2017 Cancer Center Business Summit Hosts

WELCOME

4

The firm worth listening tois the firm that listens to you.SM

Our health care clients tell us they want counsel who help them manage the sweeping challenges they face … and we’re listening. Every day, Foley attorneys provide our national, regional, and local health care industry clients with the pragmatic and creative legal solutions that keep them on track and compliant with evolving requirements.

Talk to Foley. We’re listening.SM

Foley.com

BOSTON • BRUSSELS • CHICAGO • DETROIT • JACKSONVILLE • LOS ANGELES • MADISON MIAMI • MILWAUKEE • NEW YORK • ORLANDO • SACRAMENTO • SAN DIEGO • SAN FRANCISCO

SHANGHAI • SILICON VALLEY • TALLAHASSEE • TAMPA • TOKYO • WASHINGTON, D.C.

©2016 Foley & Lardner LLP • Attorney Advertisement • Prior results do not guarantee a similar outcome • 321 N. Clark Street, Suite 2800, Chicago, IL 60654 • 312.832.4500 • 16.12331

Tell us how Foley can help you manage your health care matters. Contact Partner Michael Blau in our Boston office at [email protected].

Follow developments on Foley’s Health Care Law Today, one of the most popular health law blogs in the country. Visit Healthcarelawtoday.com.


2017 SUMMIT SPONSORS PLATINUM SPONSORSBayer HealthCare Pharmaceuticals, Inc.Cancer Treatment Centers of America®

Flatiron HealthJanssen Pharmaceutical Companies McKesson Specialty Health & The US Oncology Network Oncology Supply/ION SolutionsSg2

BRONZE SPONSORSAnimated DynamicsCardinal Health Specialty SolutionsECG Management ConsultantsHealthcare Appraisers, Inc.Integrated Healthcare Strategies, a division of Gallagher Benefit Services, Inc. marketwareOncology Management ConsultantsOncology Resource Consultants

Pinnacle Healthcare ConsultingPYARadiation Business SolutionsRevenue Cycle, Inc.RX VantageStrand DiagnosticsTEVA PharmaceuticalsUniversity of Tennessee Knoxville

GOLD SPONSORSAlliance OncologyArchway HealthEisai, Inc. Heron Therapeutics IntegraConnectLeanTaaSLilly OncologyVector OncologyVarian Medical Systems

SILVER SPONSORSCarevive Systems, Inc.Navigating CancerNew Century HealthOncology Solutions, LLCTaiho Oncology, Inc.

SPECIAL DESIGNATION SPONSORSHIPSKeynote: Cancer Treatment Centers of America and Varian Medical Systems Networking Reception: Flatiron HealthLanyard: Oncology Services InternationalAttendee Bag: McKesson Specialty Health & The US Oncology Network

6

CCBD GROUPCANCER CENTER BUSINESS DEVELOPMENT

Value-Based Alternative Payment in Oncology

CANCER CENTER BUSINESS DEVELOPMENT GROUPLeveraging the value of value-based payment in OncologyOncology Care Model (OCM) . Oncology bundled payment

analytics and design

2017 Cancer Center Business Summit

w w w.ccbdgroup.com 603.472.2285

Transforming the Business of Oncologythrough Science and Technology

Shared Savings 1 - sided risk

Pay for Enhanced

Services

Pay for Pathways

Compliance

Volume-Based Fee-for-Service

Shared Savings 2 - sided risk

Bundled PriceEpisode of Care

Oncology Medical Home*

Bundled Price Specific Treatment

?

Oncology Care Model (OCM)

MACRA

Increasing Financial Risk

Capitation

© CCBD Group. 2017


REGISTRATION & MEETING ROOMSAll meetings and events will be held at the Aria Resort. Summit event management staff will be available should you have any questions or special needs. The registration desk will be open on Sunday, February 5, 2017 from 5:00 pm to 8:00 pm. On Monday, February 6, 2017 registration for the Summit will begin at 7:00 a.m. and program sessions will commence at 8:00 a.m. In addition, there will be a networking reception immediately following the Summit Day 1 Wrap-Up.

On Tuesday, February 7, 2017 registration will begin at 6:45 a.m. and program sessions will begin at 7:30 a.m. The day will conclude at 4:15 p.m. A Networking continental breakfast will be provided both days. While in meeting rooms, please silence all cell phones and pagers. Additionally, we ask that you refrain from using all A/V recording devices.

Edward Abrahams, Ph.D. Personalized Medicine Coalition

Michael J. Anderson, M.D. Dana-Farber Community Cancer Care

Carla Balch, President NantCare

Ronald Barkley, M.S., J.D. Cancer Center Business Development Group

David C. Beyer, M.D., F.A.S.T.R.O. Arizona Oncology Services Physicians

Kelly Blair, M.P.A. Sg2

Michael L. Blau, J.D. Foley & Lardner LLP

Linda D. Bosserman, M.D., F.A.C.P. City of Hope Medical Foundation

Jennifer Carter, M.D. N-of-One

Stephanie Clayton Hobbs, M.H.S.M. UT Southwestern Medical Center

Lindsay Conway, M.S.Ed. The Advisory Board Company

Bruce Cutter, M.D., M.M.M.

Steve D’Amato, R.Ph. New England Cancer Specialists

George Daneker, Jr., M.D. Cancer Center Treatment Centers of America

Daniel Dosoretz, M.D. 21st Century Oncology

Christian Downs, J.D., M.H.A. Association of Community Cancer Centers

Robert J. Green, M.D., M.S.C.E. Flatiron Health

Teri U. Guidi, M.B.A., F.A.A.M.A. Oncology Management Consulting Group

Richard J. Hall Oncology Services International

John Hennessy, M.B.A., C.M.P.E. Wellrithms

William Jordan D.O.

Leonard K. Kalman, M.D. Miami Cancer Institute

Ira Klein, M.D., M.B.A., F.A.C.P. Janssen Pharmaceutical Companies

Michael Kolodziej, M.D. Flatiron Health

Mark Krasna, M.D. Meridian Cancer Care

Peter Kuhn, Ph.D. University of Southern California

Harlan Levine, M.D. City of Hope Medical Foundation

Kathleen G. Lokay, C.P.A. Via Oncology

Barbara L. McAneny, M.D. New Mexico Oncology Hematology Consultants

Erich Mounce, M.S.H.S. West Cancer Center

Tynan P. Olechny, M.B.A., M.P.H., C.V.A. Pershing Yoakley & Associates

Gitesh Patel Comprehensive Blood & Cancer Center

Kavita K. Patel, M.D., M.S. Brookings Institution

R. Steven Paulson, M.D. Texas Oncology

Dennis Reilly Intervention Insights

Barry Russo, M.B.A. The Center for Cancer and Blood Disorders

Lee Schwartzberg, M.D. West Cancer Center

Michael Seiden, M.D., Ph.D., McKesson Specialty Health/US Oncology

Kelley D. Simpson, M.B.A. Oncology Solutions

Mark Sobczak, M.D. Fox Chase Cancer Center

Larry Strieff, M.D. Hill Physicians Medical Group

2017 ADVISORY BOARD

8

Transforming Healthcare Through the Science and Delivery of Precision Care

Real Impact, Proven Results Over 75% of oncology

offices served nationwide

450,000 users on nationwide

network

100 million covered

lives

More than 30,000 medical devices

connected

30 million monthly payor-provider

transactions

2,000 hospitals use our

solutions


Sunday, February 5, 2017

5:00 p.m. – 8:00 p.m. Registration & Information LEVEL 3 – REGISTRATION DESK 3A

Monday, February 6, 2017

7:00 a.m. – 5:30 p.m. Registration & Information LEVEL 3 – REGISTRATION DESK 3A

7:00 a.m. – 8:00 a.m. Continental Breakfast LEVEL 3 – IRONWOOD BALLROOM 3, 5 & 8

8:00 a.m. – 8:15 a.m. Introductions and Opening Remarks LEVEL 3 – IRONWOOD BALLROOM 4

8:15 a.m. – 9:00 a.m. Washington Outlook Keynote Address LEVEL 3 – IRONWOOD BALLROOM 4 9:00 a.m.. – 10:00 a.m. Impact of Health Reform on Providers, LEVEL 3 – IRONWOOD BALLROOM 4 Payors and Cancer Patients 10:00 a.m. – 10:15 a.m. Morning Break LEVEL 3 – IRONWOOD BALLROOM 3, 5 & 8 10:15 a.m. – 11:15 a.m. Clinical Pathways: With What Result? LEVEL 3 – IRONWOOD BALLROOM 4 11:15 a.m. – 12:30 a.m. Alternative Payment in Oncology: Today & Tomorrow LEVEL 3 – IRONWOOD BALLROOM 4 12:30 p.m. – 1:30 p.m. Lunch Break LEVEL 3 – IRONWOOD BALLROOM 3, 5 & 8

SUMMIT AGENDA

LEVEL 3 – IRONWOOD BALLROOM 1 & 2 LEVEL 3 – IRONWOOD BALLROOM 6 & 7

TRACK A TRACK B

1:45 p.m. – 2:45 p.m. Integrated Practice-Hospital Affiliations MACRA: Implications for Oncologists and their Practices

2:45 p.m. – 3:00 p.m. Breakout Transition & Refreshments LEVEL 3 – IRONWOOD BALLROOMS 3, 5 & 8

TRACK A TRACK B

3:00 p.m. – 4:00 p.m. Remaining Independent: Achieving Scale through Practice Mergers & Collaborative Networks

Operational & Cultural Change


TRACK A TRACK B

4:15 p.m. – 5:15 p.m. Building the Regional Cancer Care Collaborative

Big Data Platforms to Support Community Oncology

5:15 p.m – 7:00 p.m. Networking Reception LEVEL 3 – IRONWOOD BALLROOM 3, 5 & 8

10

LATEST AGENDA UPDATES at accc-cancer.org/cancerscape

CANCERSCAPEACCC 43rd

ANNUAL MEETING

BUSINESS & POLICY, VALUE & QUALITY

MARCH 29–31, 2017RENAISSANCE WASHINGTON, DC DOWNTOWN HOTEL

Washington, D.C.

CANCERSCAPE will bring together key stakeholders from leading national organizations to share unique perspectives on this turbulent political landscape and how to successfully navigate sweeping healthcare changes. Sessions include:

n The Advisory Board Company Presents the State of Today’s Cancer Programs

n Value-Based Frameworks—Everything Your Cancer Program Needs to Know NOW

n Drug Pricing Under the Trump Administration

n Translating Lessons Learned from the Oncology Care Model to Other APMs

n It’s Here! Site Neutral Payment Policy— How It May Impact Your Program

CAPITOL HILL DAYMARCH 29, 2017 It’s now more important than ever to engage with your Congressional representatives and make your voice heard. No need to be a “policy expert” or familiar with specific legislation to advocate for improved funding and access to quality oncology care.

Capitol Hill Day is included with your CANCERSCAPE registration.


LEVEL 3 – IRONWOOD BALLROOM 1 & 2 LEVEL 3 – IRONWOOD BALLROOM 6 & 7

TRACK A TRACK B

12:45 p.m. – 1:45 p.m. The Oncology Care Model (OCM) Evolving Best Practices

Supply Chain Disruption and Innovation


TRACK A TRACK B

2:00 p.m. – 3:00 p.m. Opportunities in Patient-Centered Care Delivery Models

Palliative Care Solutions


TRACK A TRACK B

3:15 p.m. – 4:15 p.m. Oncology Business Transactional Issues Enabling Patient Engagement

Tuesday, February 7, 2017

6:30 a.m. – 8:15 a.m. Continental Breakfast LEVEL 3 – IRONWOOD BALLROOM 3, 5 & 8

7:00 a.m. – 5:30 p.m. Registration & Information LEVEL 3 – REGISTRATION DESK 3A

7:30 a.m. – 8:15 a.m. Legal & Regulatory Update LEVEL 3 – IRONWOOD BALLROOM 4

8:30 a.m. – 9:30 a.m. Technology Innovations for a LEVEL 3 – IRONWOOD BALLROOM 4 Better Tomorrow in Oncology

9:30 a.m. – 10:30 a.m. Incorporating Genomic Science into the LEVEL 3 – IRONWOOD BALLROOM 4 Community Oncology Setting

10:30 a.m. – 10:45 a.m. Morning Break LEVEL 3 – IRONWOOD BALLROOM 3, 5 & 8

10:45 a.m. – 11:45 a.m. Oncology Office of the Future LEVEL 3 – IRONWOOD BALLROOM 4

11:45 a.m. – 12:45 p.m. Lunch Break LEVEL 3 – IRONWOOD BALLROOM 3, 5 & 8

SUMMIT AGENDA (Continued)

12

“My patients have

to make. I want to give them choices.”

“My patients have

to make.I want to give them choices.”

“We’re committedto helping you

give your patients more options

”

Bayer and the Bayer Cross are registered trademarks of Bayer. © 2016 Bayer HealthCare Pharmaceuticals, Inc. PP-900-US-1930


7:00 a.m. – 5:30 p.m.LEVEL 3 – REGISTRATION DESK 3ARegistration & Information

7:00 a.m. – 8:00 a.m.LEVEL 3 – IRONWOOD BALLROOM 3, 5 & 8 Continental Breakfast

8:00 a.m. – 8:15 a.m.LEVEL 3 – IRONWOOD BALLROOM 4Introductions and Opening Remarks Michael L. Blau, J.D., Chair, Industry Teams and Partner, Foley & Lardner LLP; Co-Founder of Cancer Center Business Summit

8:15 a.m. – 9:00 a.m. LEVEL 3 – IRONWOOD BALLROOM 4Washington Outlook Keynote AddressWilliam Frist, M.D., 18th Majority Leader, U.S. Senate (2003-2007)

Dr. Frist will describe what we can anticipate regarding health policy changes under the Trump Administration and identify the implications for the delivery of community cancer care. As a nationally-acclaimed heart and lung transplant surgeon and a former U.S. Senator, Dr. Frist is uniquely qualified to access and interpret the new Administration’s initial health policy positions.

The Washington Outlook Keynote Address is supported through the generous contributions of Cancer Treatment Centers of America and Varian Medical Systems

9:00 a.m. – 10:00 a.m.LEVEL 3 – IRONWOOD BALLROOM 4Impact of Health Reform on Providers, Payors and Cancer Patients Moderator: Mike Kolodziej, M.D., National Medical Director, Managed Care Strategy, Flatiron Health

Panelists: Alan Balch, Ph.D., Chief Executive Officer, Patient Advocate Foundation

Steve D’Amato, R.Ph., Executive Director, New England Cancer Specialists

Daniel Hilferty, President and Chief Executive Officer, Independence Health Group

Harlan Levine, M.D., Chief Strategy Officer, City of Hope and Chief Executive, City of Hope Medical Foundation

How is health reform impacting oncology providers and cancer patients? Reform by regulatory fiat…added costs, added anxiety, what are we actually accomplishing? Panelists will address the issues from the viewpoint of the patient; of health plans; of community oncology practice and of health systems/AMCs.

MONDAY, FEBRUARY 6, 2017

SUNDAY, FEBRUARY 5, 20175:00 p.m. – 8:00 p.m.LEVEL 3 – REGISTRATION DESK 3A Registration & Information

14

Atlanta

Chicago

Philadelphia

Phoenix

Tulsa

Cancer Treatment Centers of America® (CTCA) is a network of five hospitals across the U.S. offering an integrative approach to cancer care. CTCA® combines advanced technologies to fight cancer and evidence-informed therapies to help reduce side effects. Our precision cancer treatments provide our patients with truly personalized care. For more information on CTCA, visit cancercenter.com or contact us at [email protected].

© 2017 Rising Tide

Two breakthrough medical approaches have revealed new possibilities in cancer treatment— and they are available today at Cancer Treatment Centers of America® (CTCA).

We’re not just fighting cancer. Now we’re outsmarting it.

u IMMUNOTHERAPY

u ADVANCED GENOMIC TESTING Why does one patient’s breast or lung cancer respond differently to the same treatment than another patient’s?

The answer is that the cancers are different on the molecular level. At CTCA®, we may now be able to identify the DNA alterations that drive a cancer’s growth, leading to treatments that target those alterations and potentially reveal treatment options that had not been considered previously.

These targeted, personalized treatments may give patients more opportunities to fight cancer—today.

Our bodies fight off the viruses and bacteria that make us sick. Why not cancer?

New drugs may help fight cancer by turning off the signals that tell immune cells to stop fighting. Others kick-start immune responses against certain cancers or help the body generate super-charged cancer-killing immune cells.

By unleashing the body’s immune system to fight cancer, immunotherapy gives many patients more options in their fight against cancer.

Until recently, doctors defined cancer by the organ where it was first discovered.

Advanced genomic testing can help fight an individual patient’s cancer at the molecular level, regardless of where in the body it originated.

New therapies can help teach immune systems to recognize and destroy cancer cells.

Our immune systems do not recognize cancer cells as a threat.

AT C TC A, C A N C E R T R E AT M E N T G E TS

personal

Immunotherapy and advanced genomic testing are different disciplines, but they both focus on the individual. This personalized approach is what makes them so promising.


MONDAY, FEBRUARY 6, 2017 (Continued)10:00 a.m. – 10:15 a.m.LEVEL 3 – IRONWOOD BALLROOM 3, 5 & 8Morning Break

10:15 a.m. – 11:15 a.m.LEVEL 3 – IRONWOOD BALLROOM 4Clinical Pathways: With What Result? Moderator: Mark Sobczak, M.D., Clinical Director, Fox Chase Cancer Center

Panelists: Andrew Hertler, M.D., Chief Medical Officer, New Century Health

Constantine Mantz, M.D., Chief Medical Officer, 21st Century Oncology

Marcus Neubauer, M.D., Medical Director Oncology Services, McKesson Specialty Health & The US Oncology Network

In this session, panelists will explore how the use of clinical pathways/guidelines have changed clinical practice in oncology and will address the manner in which pathways have created value.

11:15 a.m. – 12:30 p.m.LEVEL 3 – IRONWOOD BALLROOM 4 Alternative Payment in Oncology: Today & TomorrowModerator: Ronald Barkley, M.S., J.D., President, Cancer Center Business Development Group

Panelists: Kelly Blair, M.P.A., Vice President Consulting, Sg2

Lili Brillstein, M.P.H., Director Episodes of Care, Horizon Blue Cross Blue Shield of New Jersey

Larry Strieff, M.D., Specialty Medical Director, Hill Physicians Medical Group

Cynthia Terrano, Vice President Payer Strategies, Moffitt Cancer Center

Dave Terry, Chief Executive Officer, Archway Health

In this session, panelists will describe their experience with Alternative Payment Models (APMs) in oncology. What oncology APMs are in place today and what have been the results? Are we headed toward assumption of full financial risk in oncology? If so, what form does risk take and what are the impediments to success? Is retrospective shared savings going to be the predominate APM in oncology or can we anticipate prospective bundled pricing on a broad scale in oncology any time soon?

12:30 p.m. – 1:30 p.m.LEVEL 3 – IRONWOOD BALLROOM 3, 5 & 8 Lunch Break

16

It takes more than an EHR to prepare you for the future of oncology. Flatiron’s OncoCloud technology suite supports oncology practices in a constantly evolving healthcare environment. Our world-class engineers and oncology professionals guide continuous product development, arming you with better ways to address key clinical, financial and operational concerns.

Operational Efficiency

Financial Health

Quality o

f Car

e

Revenue CycleManagement

Value-basedCare

OncoAnalytics®

OncoTrialsTM

OncoBilling®

OncoEMR®

[email protected]

ONCOCLOUD SERVES:

1 in 9U.S. patients diagnosed with cancer

260+community practices & cancer centers

2400+clinicians

flatiron.com


MONDAY, FEBRUARY 6, 2017 (Continued)

Track ALEVEL 3 – IRONWOOD BALLROOM 1 & 2Integrated Practice-Hospital AffiliationsModerator: Michael L. Blau, J.D., Chair, Industry Teams and Partner, Foley & Lardner LLP

Panelists: Warren Benincosa, Chief Executive Officer, Cancer Care Northwest

Matthew Schneider, Associate Vice President Oncology, HonorHealth

Lee Schwartzberg, M.D. Chief, Division of Hematology Oncology, Professor of Medicine, University of Tennessee and Director, West Cancer Center

This session will explore the business case and models for oncology practice-hospital alignment. Affiliation models that position stakeholders for OCM, clinical integration, and financial risk sharing will be discussed. Case studies of Joint Ventures, Professional Service Agreements, Co-Management Arrangements and Virtual Employment will be presented. Speakers will address deal maker/breaker issues, operational and technology integration challenges, lessons learned, and impacts on patients, providers and payers. Recent legal developments affecting alignment transaction structures will also be reviewed, including the new 340B Omnibus Guidance, the Cures Bill, Medicare site of service neutrality regulations, and proposed Part B Drug payment rules.

1:45 p.m. – 2:45 p.m. Breakout SessionsTrack BLEVEL 3 – IRONWOOD BALLROOM 6 & 7 MACRA: Implications for Oncologists and their PracticesModerator: Linda Bosserman, M.D., City of Hope Medical Foundation

Panelists: Jessica Turgon, M.B.A., Principal, ECG Management Consultants

Robin Zon, M.D., Michiana Hematology Oncology

Update on final rule and MACRA options for different practice settings as well as practical decision making and implementation approaches taken by various practices across the Country.

2:45 p.m. – 3:00 p.m.LEVEL 3 – IRONWOOD BALLROOM 3, 5 & 8 Breakout Transition & Refreshments

18

wants to thank you all for the incredibly important work you do each day.

© Janssen Biotech, Inc. 2016 01/16 043910-151125

Janssen Biotech, Inc.

Betsy Gross, Lilies and Carp

Artwork from The Creative Center at University Settlement

043910-151125_746798_CCBS_Thank_You_Ad_8.5x11_v1a.indd 1 1/14/16 1:38 PM


MONDAY, FEBRUARY 6, 2017 (Continued)3:00 p.m. – 4:00 p.m. Breakout SessionsTrack ALEVEL 3 – IRONWOOD BALLROOM 1 & 2Remaining Independent: Achieving Scale through Practice Mergers & Collaborative NetworksModerator: Christian Downs, J.D., M.H.A., Executive Director, Association Community Cancer Centers

Panelists: Sibel Blau, M.D., Northwest Medical Specialties & Quality Cancer Care Alliance

Atul Dhir, M.D., D.Phil, Chief Executive Officer, New Century Health

Randy Hyun, Senior Vice President/General Manager Provider Solutions, McKesson Specialty Health

A real time look at current models that practices and hospitals can use to maintain independence for their physicians. Special emphasis will also be placed on emerging models and challenges that exist in achieving scale and maintaining independence.

Track BLEVEL 3 – IRONWOOD BALLROOM 6 & 7Operational & Cultural ChangeModerator: Erich Mounce, M.S.H.S., Chief Executive Officer, West Cancer Center

Panelists: Sarah Chavarria, Chief People Officer, NantHealth

James Grayson, High Reliability Organization Specialist, West Cancer Center

Barry Russo, M.B.A., Chief Executive Officer, The Center for Cancer and Blood Disorders

What does it take in the way of resource and talent planning to run a smooth operation in a rapidly changing care delivery system? Panelists will address such subjects as staff retention; care team building and effective team-based care

4:00 p.m. – 4:15 p.m. LEVEL 3 – IRONWOOD BALLROOM 3, 5 & 8 Breakout Transition & Refreshments

20

usoncology.com

With more than 1,400 independent physicians treating over 800,000 patients annually, The US Oncology

Network manages the health of your practice so you can focus on the health of your patients.

Together we’re leading the shift to value-based care, with our oncologists representing one-fourth of all

of the physicians participating in the OCM.

We understand community oncology

care because we’re a part of it.

Patircia Rodriguez, M.D.

Virginia Cancer Specialists

Together, we’re delivering exceptional value-based care.McKesson Specialty Health’s deep business relationships across the healthcare system help thousands of community oncology practices successfully navigate the changing reimbursement landscape.

Partner with us to get the expertise and practical solutions that help you adopt new technology, adapt your clinical regimens, and maintain financial stability so that your patients always have the choice of quality care close to home.

Visit McKessonSpecialtyHealth.com to learn more.

Manufacturers Payers

Providers Policy

Patients


4:15 p.m. – 5:15 p.m.Track ALEVEL 3 – IRONWOOD BALLROOM 1 & 2Building the Regional Cancer Care CollaborativeModerator: John Hennessy, M.B.A., C.M.P.E. Senior Vice President, Wellrithms

Panelists: Michael Blau, J.D., Chair, Industry Teams and Partner, Foley & Lardner LLP;

Mark Krasna, M.D., Corporate Medical Director, Meridian Cancer Care

Anthony Melaragno, M.D., Vice President Behavioral Health and Oncology Services, Legacy Health

Leonard Sender, M.D., Senior Vice President Pediatric & Young Adult Cancer Medical Affairs, NantKwest

There has been widespread concern in healthcare that mergers and acquisitions are merely moving pieces on the chessboard and not advancing the quality and value of care. In this session, we will explore the promise and preliminary results from early innovators who have established oncology collaboratives that are patient-focused and value-conscious. These collaboratives are regional systems of cancer care that span a continuum of providers to cover a broad geographic region of patients, while avoiding unnecessary duplication of investment and services. Case studies of collaboratives among academic medical centers, community hospitals and community-based oncology groups will be presented. Topics will include successful models for aligning interests through shared governance and economics in support of multi-disciplinary care coordination and delivery, as well as in support of cutting edge genomics and immunology research trials on a regional basis.

5:15 p.m. – 7:00 p.m. LEVEL 3 – IRONWOOD BALLROOM 3, 5 & 8Networking Reception

The 2017 Networking Reception is supported through the generous contribution of Flatiron Health

MONDAY, FEBRUARY 6, 2017 (Continued)

Track BLEVEL 3 – IRONWOOD BALLROOM 6 & 7Big Data Platforms to Support Community Oncology Moderator: Carla Balch, President, NantCare

Panelists: James Hamrick, M.D., Senior Medical Director, Flatiron Health

Robert S. Miller, M.D., Vice President & Medical Director, CancerLinQ

Deborah Patt, M.D., M.P.H., M.B.A., Vice President, Texas Oncology, Medical Director – Analytics, The US Oncology Network, Editor in Chief – JCO-Clinical Cancer Informatics

Vasu Rangadass, Ph.D., Chief Strategy Officer, NantHealth

Topics to be addressed during this session include: data interoperability, connecting patients and caregivers; artificial intelligence; using real world evidence/data to treat patients; how will technology affect patients, providers and decision making?

22

Let Us Be YourChoicePartner Of

Trusted.Efficient.Innovative

Technology solutions that reduce costs, optimize reimbursement, and improve staff productivity, accuracy, & performance.

Comprehensive peer-to-peer networking & education programs.

Insight regarding healthcare policy, inventory management, physician dispensing, and other trends that impact your site of care.

We provide

With our extensive industry network & distribution experience, we have the knowledge, guidance, collective buying power, and purchasing programs to help independent oncologists succeed.


TUESDAY, FEBRUARY 7, 20176:30 a.m. – 8:15 a.m. LEVEL 3 – IRONWOOD BALLROOM 3, 5 & 8Networking Continental Breakfast

7:00 a.m. – 5:30 p.m.LEVEL 3 – REGISTRATION DESK 3ARegistration & Information

7:30 a.m. – 8:15 a.m. LEVEL 3 – IRONWOOD BALLROOM 4Legal & Regulatory Update Moderator: Alan Einhorn, Esq., Foley & Lardner, LLP

Panelists: Donald Romano, Esq., Foley & Lardner, LLP

Anil Shankar, Esq., Senior Counsel, Foley & Lardner, LLP

James M. Tudor, C.P.C., P.C.A., Director Billing Compliance, Healthcare Compliance Network

After a brief overview from Alan Einhorn, Don Romano will explain the Quality Payment Program, enacted by MACRA, with special emphasis on the Oncology Care Model as an Alternative Payment Model, Anil Shankar will cover the 340B Program, including key compliance issues and an update on the future of the Program, and Jim Tudor will discuss best practice phraseology as it pertains to coding common scenarios in the oncology universe (including EMR pitfalls, E/M documentation do’s and don’ts, and billing by time).

8:30 a.m. – 9:30 a.m.LEVEL 3 – IRONWOOD BALLROOM 4Technology Innovations for a Better Tomorrow in Oncology Moderator: Christian Downs, J.D., M.H.A., Executive Director, Association Community Cancer Centers

Panelists: Jon DeVries, Director Offering Manager, IBM Watson

Sukhveer Singh, Vice President/General Manager, Oncology Continuum Solutions, Varian Medical Systems

Krishna Yeshwant, MD, Partner, GV (formerly Google Ventures)

Up to the minute overview of technologies that will revolutionize the way oncology care is delivered and quantified. Consideration will be given to determining value and affordability along with addressing implementation challenges.

24

Where are opportunities to improve loyalty for my

af�liated physicians?Where are patients

receiving radiation therapy from my af�liated urologists?

Are my employed physicians leaking patients to other providers?

Am I pursuing the best partners for my cancer center?


TUESDAY, FEBRUARY 7, 2017 (Continued)

9:30 a.m. – 10:30 a.m.LEVEL 3 – IRONWOOD BALLROOM 4Incorporating Genomic Science into the Community Oncology Setting Moderator: Carla Balch, President, NantCare

Panelists: Robert Green, M.D., M.S.C.E, Senior Vice President, Clinical Oncology, Flatiron Health

Todd Hembrough, Ph.D., President, Proteomics NantOmics, LLC

Jonathan Hirsch, President and Founder, Syapse

Tracey Weisberg, M.D., President, New England Cancer Specialists

How are all the new "omics" sciences being received in the community oncology setting? Education and implementation challenges and how they are being solved in order to incorporate the new clinical science into the community practice standard of care.

10:30 a.m. – 10:45 a.m.LEVEL 3 – IRONWOOD BALLROOM 3, 5 & 8Morning Break

10:45 a.m. – 11:45 a.m.LEVEL 3 – IRONWOOD BALLROOM 4 Oncology Office of the Future Moderator: Erich Mounce M.S.H.S., Chief Executive Officer, West Cancer Center

Panelists: Keith Cowing, Director of Product Management, Flatiron Health

Mohan Giridharadas, Chief Executive Officer, LeanTaaS

Robert Green, M.D., M.S.C.E, Senior Vice President, Clinical Oncology, Flatiron Health

John Lee, M.D., Cancer Center Director, Chan Soon-Shiong Institute of Molecular Medicine

Edward Stepanski, Ph.D., Chief Operating Officer, Vector Oncology

Tying it all together: the new science and new technologies in the community oncology setting. Essential elements: people, plant & equipment. Dealing effectively with IT technology; implementation and management in a cost control environment; how to organize your practice to incorporate omics/ precision medicine, support services, clinical trials, immunotherapy and remain financially sustainable.

11:45 p.m. – 12:45 p.m.LEVEL 3 – IRONWOOD BALLROOM 3, 5 & 8Lunch Break

26

Archway Health

ARCHWAY HEALTH Archway Health is a healthcare business innovator working with providers and payers to design and execute care and risk management programs for Bundled Payment contract success.. A program innovator since the inception of the CMS Bundled Payment initiative, Archway is currently at work on BPCI, CJR and OCM contracts along with commercial bundle programs with dozens of providers and payers across the country.

Oncology Care Suite: A Proprietary Bundled Payment Program Platform for Oncology Care Specialists offering:

•  Program Analytics •  OCM Program Complaince •  Risk and Care Management


TUESDAY, FEBRUARY 7, 2017 (Continued)12:45 p.m. – 1:45 p.m. Breakout SessionsTrack ALEVEL 3 – IRONWOOD BALLROOM 1 & 2The Oncology Care Model (OCM) Evolving Best Practices Moderator: Ronald Barkley, M.S., J.D., President Cancer Center Business Development Group

Panelists: Ed Bassin, Ph.D., Chief Analytics Officer, Archway Health

Brenton Fargnoli, M.D., Associate Medical Director Strategic Initiatives, Flatiron Health

Barbara McAneny, M.D., Chief Executive Officer, New Mexico Oncology Hematology Consultants and National Cancer Care Alliance

Diana Verrilli, Vice President/General Manager Managed Care, Quality and Provider Solutions, McKesson Specialty Health

Panelists will explore the current status of the OCM program and identify the evolving “best practices” for OCM operations. How is quality and clinical data being accessed, interpreted and reported to comply with OCM data reporting requirements? What steps are OCM Participants taking in order to understand their claims data and to gauge their progress toward earning Performance-Based Payment (PBP), particularly with regard to electing 2-sided risk?

Track BLEVEL 3 – IRONWOOD BALLROOM 6 & 7Supply Chain Disruption and Innovation Moderator: Ira Klein, M.D., M.B.A., Senior Director Quality, Strategic Customer Group, Janssen Pharmaceutical Companies

Panelists: Lindsay Conway, M.S.Ed. Managing Director Oncology Roundtable, The Advisory Board Company

Matt Farber, M.A., Senior Director Oncology Disease State, Walgreens

Jeffrey Scott, M.D., Chief Medical Officer, IntegraConnect

As healthcare providers and delivery systems shift from volume to value based payment as a result of MACRA, key questions arise about the present supply chain system of drugs from manufacturer to provider and patient. What about the comparative costs of drugs, specialty Rx and shift to oral chemotherapy, and who is delivering and coordinating therapy? Are we managing this appropriately? Who is aware of opportunities to achieve the goals of better, smarter, cheaper care, and how would we do this? Who is taking risk and who is taking profit? Where are the incentives? The panel will discuss the complexities of the present supply chain, and what tools, motivations, and relationships can drive supply chain disruption into better and more innovative model(s) demanded of us for the future.


28

HERON THERAPEUTICSis a proud sponsor of the

Cancer CenterBusiness Summit

© 2017 Heron Therapeutics, Inc. All rights reserved. 01/17 PP-HCB-0040 herontx.com


TUESDAY, FEBRUARY 7, 2017 (Continued)2:00 p.m. – 3:00 p.m. Breakout SessionsTrack ALEVEL 3 – IRONWOOD BALLROOM 1 & 2Opportunities in Patient-Centered Care Delivery Models Moderator: Michael Blau, J.D., Chair, Industry Teams and Partner, Foley & Lardner LLP

Panelists: Jennie Crews, M.D., Medical Director SCCA Network and Research Integration, Seattle Cancer Care Alliance

Kelly Hall, Managing Principal, Transformative Impact, Health Leads

Madelyn Herzfeld, R.N., B.S.N., O.C.N., Chief Executive Officer, Carevive Systems

Andy Shin, J.D., M.P.H., Senior Director Policy & Strategic Partnerships, The Schwartz Center for Compassionate Care

Social determinants of health and psychosocial issues can account for as much as 60% of the health outcomes of patients. Yet, most oncology service lines and practices have little or no programs to address these issues. This is because, traditionally, these issues have been viewed as social welfare and not health care matters, and because, historically, there has been no return on the investment for developing these programs. That is now changing. With CMMI’s Accountable Communities Model, OCM and other alternative payment arrangements, community oncology stakeholders have new opportunities and incentives to prioritize their health care spend on effective patient centered care models that improve patient outcomes and health. Also, new tools are now available to help address these social welfare issues, as well as genetics counseling, palliative care and other non-clinical interventions that impact health. These tools can change the cost/benefit equation and provide a feasible business case for developing and implementing such patient-centered support programs. In this session, speakers will explore the evidence-based support for the effectiveness of these programs and will discuss their associated economics.

Track BLEVEL 3 – IRONWOOD BALLROOM 6 & 7Palliative Care SolutionsModerator: John Hennessy, M.B.A., C.M.P.E. Senior Vice President, Wellrithms

Panelists: J. Russell Hoverman, M.D., Ph.D., Vice President Quality Programs, Texas Oncology/Medical Director Managed Care McKesson Specialty Health & The US Oncology Network

Christian T. Sinclair, M.D., Assistant Professor Palliative Medical Division, University of Kansas Medical Center

Mark Wrona, M.D., New England Cancer Specialists

2016 was an exciting time in palliative care. The third annual Palliative Care in Oncology Symposium was held in September. ASCO updated palliative care guidelines. COME HOME practices shared more data about palliative care in that model. This session will explore the “best of” highlights from each of these events.



TUESDAY, FEBRUARY 7, 2017 (Continued)3:15 p.m. – 4:15 p.m. Breakout SessionsTrack ALEVEL 3 – IRONWOOD BALLROOM 1 & 2Oncology Business Transactional Issues Moderator: Adria Warren, J.D., Partner, Foley & Lardner LLP

Panelists: Curtis Bernstein, C.P.A., M.B.A., Principal, Pinnacle Healthcare Consulting

Tynan P., M.B.A., M.P.H., C.V.A., Consulting Principal, Pershing Yoakley & Associates

In a world of proliferating alternative payment models (APMs), continuing hospital/oncology practice alignment, and increasing regulatory scrutiny, fair market value remains a complex and crucial consideration for all providers. Our panel of experts will discuss the current trends in transaction valuation, and the “top ten” most challenging issues oncologists can expect to face at the point of transaction, and over the lifetime of an affiliation. Join us to learn about those valuation challenges – and possible solutions – in connection with the adoption of APMs; provider mergers and acquisitions, alignment and integration; service line joint ventures; professional services, management and co-management arrangements; hospital quality and efficiency programs; gainsharing; and accountable care.

Track BLEVEL 3 – IRONWOOD BALLROOM 6 & 7Enabling Patient EngagementModerator: Linda Bosserman, M.D., City of Hope Medical Foundation

Panelists: Gena Cook, Chief Executive Officer, Navigating Cancer

Ashley Pandya, Manager Strategy and Innovation, HopeLab

Deirdre Saulet, Ph.D., The Advisory Board Company

Understanding options for patient engagement for self-care, interval care management, with integrated triage management, for shared decision making and performance tracking. Technologies, tools and practice processes that enable patient engagement with approaches to meeting these needs as practices transition to value based care models, such as the OCM program.

www.CancerBusinessSummit.com 32www.CancerBusinessSummit.com

Alan Balch, Ph.D.Chief Executive Officer, Patient Advocate Foundation Hampton, Virginia

Warren BenincosaChief Executive Officer, Cancer Care Northwest Spokane, Washington

Sibel Blau, M.D.Northwest Medical Specialties Puyallup, Washington

Lindsay Conway, M.S. Ed.Managing Director Oncology Roundtable, The Advisory Board Company Washington, DC

Carla BalchPresident, NantCareLos Angeles, California

Curtis Bernstein, C.P.A., M.B.A. Principal, Pinnacle Healthcare ConsultingCentennial, Colorado

Linda Bosserman, M.D., F.A.C.P.Clinical Assistant Professor, City of Hope Medical FoundationDuarte, California

Gena CookCo-Founder and Chief Executive Officer, Navigating CancerSeattle, Washington

Ronald Barkley, M.S., J.D.President, Cancer Center Business Development GroupCo-Founder Cancer Center Business SummitBedford, New Hampshire

Kelly Blair, M.P.A.Vice President, Consulting, Sg2Skokie, Illinois

Lili Brillstein, M.P.H.Director Episodes of Care Horizon Blue Cross Blue Shield of New Jersey Maplewood, New Jersey

Keith CowingDirector of Product Management Flatiron Health New York, New York

Ed Bassin, Ph.D.Chief Analytics Officer, Archway HealthBoston, Massachusetts

Michael L. Blau, J.D.Chair, Industry Teams and Partner, Foley & Lardner LLPCo-Founder Cancer Center Business SummitBoston, Massachusetts

Sarah ChavarriaChief People Officer NantHealthLos Angeles, California

Jennie Crews, M.D., M.M.M.Medical Director SCCA Network and Research Integration Seattle Cancer Care AllianceSeattle, Washington

2017 DISTINGUISHED FACULTY

32


Steve D’Amato, R.Ph.Executive Director, New England Cancer Specialists Scarborough, Maine

Alan Einhorn, Esq.Foley & Lardner, LLPBoston, Massachusetts

Mohan Giridharadas, M.B.A.Chief Executive Officer, LeanTaaSSanta Clara, California

James Hamrick, M.D.Senior Medical Director, Flatiron HealthNew York, New York

Madelyn Herzfeld, R.N., B.S.N., O.C.N.Chief Executive Officer, Carevive SystemsNorth Miami, Florida

Jon DeVriesDirector, Offering Manager IBM WatsonRaleigh-Durham, North Carolina

Matthew Farber, M.A.Senior Director Oncology Disease State, WalgreensWashington, DC

James GraysonHigh Reliability Organization Specialist, West Cancer Center Memphis, Tennessee

Todd Hembrough, Ph.DPresident, Proteomics NantOmics, LLC Rockville, Maryland

Daniel HilfertyPresident and Chief Executive Officer, Independence Health GroupPhiladelphia, Pennsylvania

Atul Dhir, MD, D.Phil Chief Executive Officer, New Century Health Wellesley, Massachusetts

Brenton Fargnoli, M.D.Associate Medical Director Strategic Initiatives, Flatiron Health New York, New York

Bobby Green, M.D., MSCESenior Vice President, Clinical Oncology, Flatiron HealthNew York, New York

John Hennessy, M.B.A., C.M.P.E.Senior Vice President, Wellrithms Overland Park, KS

Jonathan HirschPresident & Founder SyapsePalo Alto, California

Christian Downs, J.D., M.H.A. Executive Director, Association Community Cancer CentersRockville, Maryland

Bill Frist, M.D.18th Majority Leader, U.S. Senate (2003-2007)Nashville, Tennessee

Kelly HallManaging Principal, Transformative Impact, Health LeadsBoston, Massachusetts

Andrew Hertler, M.D.Chief Medical Officer, New Century HealthWellesley, Massachusetts

J. Russell Hoverman, M.D., Ph.D.Vice President Quality Programs, Texas Oncology/Medical Director Managed Care McKesson Specialty Health & The US Oncology NetworkAustin, Texas

www.CancerBusinessSummit.com 3434 www.CancerBusinessSummit.com

Randy HyunSenior Vice President & General Manager, Provider Solutions McKesson Specialty HealthThe Woodlands, Texas

John Lee, M.D.Cancer Center Director, Chan Soon-Shiong Institute of Molecular Medicine Los Angeles, California

Anthony Melaragno, M.D.Vice President Behavioral Health and Oncology Services, Legacy HealthPortland, Oregon

Tynan P. Olechny, M.B.A., M.P.H., C.V.A.Consulting Principal, Pershing Yoakley & Associates Atlanta, Georgia

Donald Romano, Esq. Foley & Lardner, LLPWashington, DC

Ira Klein, M.D., M.B.A., Senior Director Quality Strategic Customer Group, Janssen Pharmaceutical CompaniesRaritan, New Jersey

Harlan Levine, M.D.Chief Strategy Officer, City of HopeChief Executive, City of Hope Medical FoundationDuarte, California

Robert S. Miller, M.D.Vice President & Medical Director, CancerLinQAlexandria, Virginia

Ashley PandyaManager Strategy and Innovation, HopeLabRedwood City, California

Barry Russo, M.B.A.Chief Executive Officer, The Center for Cancer and Blood Disorders Fort Worth, Texas

Michael Kolodziej, M.D.National Medical Director, Managed Care Strategy, Flatiron HealthNew York, New York

Constantine Mantz, M.D.Chief Medical Officer, 21st Century OncologyFt. Meyers, Florida

Erich Mounce, M.S.H.S.Chief Executive Officer, West Cancer Center Memphis, Tennessee

Debra Patt, M.D., M.P.H., M.B.A.Vice President, Texas OncologyMedical Director - Analytics, The US Oncology NetworkEditor in Chief, JCO-Clinical Cancer InformaticsAustin, Texas

Deirdre Saulet, Ph.D.Senior Consultant, The Advisory Board CompanyWashington, DC

Mark Krasna, M.D.Corporate Medical Director, Meridian Cancer Care Neptune, New Jersey

Barbara McAneny, M.D.Chief Executive Officer, New Mexico Oncology Hematology Consultants Albuquerque, New Mexico

Marcus Neubauer, M.D.Medical Director of Oncology Services, McKesson Specialty Health & The US Oncology NetworkSeattle, Washington

Vasu Rangadass, Ph.D.Chief Strategy Officer, NantHealthDallas, Texas

Matthew SchneiderAssociate Vice President Oncology, HonorHealthScottsdale, Arizona

34


Lee Schwartzberg, M.D.Chief, Division of Hematology Oncology, Professor of Medicine, University of Tennessee Director, West Cancer CenterMemphis, Tennessee

Andy Shin, J.D., M.P.H.Senior Director Policy & Strategic Partnerships, The Schwartz Center for Compassionate CareBoston, Massachusetts

Ed Stepanski, Ph.D.Chief Operating Officer, Vector OncologyMemphis, Tennessee

James Tudor, C.P.C., P.C.A.Director of Billing Compliance, Healthcare Compliance NetworkHudson, Massachusetts

Tracey Weisberg, M.D.President, New England Cancer SpecialistsScarborough, Maine

Jeffrey Scott, M.D.Chief Medical Officer, IntegraConnectJupiter, Florida

Christian Sinclair, M.D.Assistant Professor Palliative Medical Division, University of Kansas Medical Center Kansas City, Kansas

Larry Strieff, M.D.Specialty Medical Director, Hill Physicians Medical Group San Ramon, California

Jessica Turgon, M.B.A.Principal, ECG Management ConsultantsWashington, DC

Mark Wrona, M.D. New England Cancer Specialists Scarborough, Maine

Leonard Sender, M.D.Senior Vice President Pediatric & Young Adult Cancer Medical Affairs, NantKwest Los Angeles, California

Sukhveer SinghVice President & General Manager, Oncology Continuum Solutions, Varian Medical Systems Palo Alto, California

Cynthia TerranoVice President Payer Strategies, Moffitt Cancer Center Tampa, Florida

Diana VerrilliSVP, Payer and Practice Management Solutions Quality and Provider Solutions, McKesson Specialty Health Denver, Colorado

Krishna Yeshwant, M.D.Partner, GV (formerly Google Ventures)Cambridge, Massachusetts

Anil Shankar, Esq.Senior Counsel Foley & Lardner, LLPLos Angeles, California

Mark Sobczak, M.D.Clinical Director, Fox Chase Cancer CenterPhiladelphia, Pennsylvania

Dave Terry, M.B.A.Chief Executive Officer, Archway HealthWatertown, Massachusetts

Adria Warren, J.D.,PartnerFoley & Lardner LLPBoston, Massachusetts

Robin Zon, M.D.Michiana Hematology OncologyMishawaka, Indiana

36

13:00 21:007:00

30

40

50

20

10

013:00 21:007:00

37

VISIT LARTRUVO.COM/approvalFOR MORE INFORMATION

PP-OR-US-0003 10/2016 © Lilly USA, LLC 2016. All rights reserved.

LARTRUVOTM is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affi liates.

NOW FDA APPROVED

S:7.375”

S:10.5”

T:7.875”

T:11”

B:8.5”

B:11.375”

10490841_NowApproved_JournalAD_FR2.indd 1 9/29/16 3:17 PM

38

© 2016, 2017 Varian Medical Systems, Inc. All rights reserved. Varian and Varian Medical Systems are registered trademarks, and 360 Oncology is a trademark of Varian Medical Systems, Inc.

Varian 360 Oncology™ care management allows instant collaboration across your teams and disciplines, giving you a 360-degree view of your patients. It takes your clinic’s data, records and patient information and connects them in one platform, making once hard-to-access information immediately available to your entire cancer-fighting team. With this simple yet comprehensive solution, you can make more confident decisions while connecting with patients throughout their entire cancer-care journey—from screening through survivorship.

Learn more at varian.com/360

Connect. Collaborate. Coordinate.

40

Alliance Oncology provides their partners with:

• O�-Balance Sheet Capital to share risks and benefits of assets and liabilities

• Operational Expertise to optimize clinical quality and patient satisfaction

• Oncology Specific Marketing to increase referrals and market share

• State-of-the-art Technology and Training to enhance patient care

• Hospital and Physician Alignment to unify and strengthen the market

Comprehensive Partnerships forHospitals and Radiation Oncologists

Contact us to discuss the growthof your oncology service line

615.263.7888 / [email protected]

Alliance Oncology, an industry leader in oncology service line development, creates joint venture partnerships with hospitals, physicians and other healthcare providers to establish, operate and expand cancer care.

41

PROVEN LEADER IN RISK-BASED ONCOLOGY QUALITY MANAGEMENT SOLUTIONS

Your Partner In Value-Based Oncology Programs

Oncology Practices

Accountable Care Organizations

Patient Centered Medical Homes

15 years of experience

Improving care quality for more than 7 million Medicare, Commercial and Medicaid members

Partnering with more than 8,000 oncologists nationwide

State of-the-art clinical decision support

Curated pathways for most cancers

Advanced Analytics

Risk Stratification

Provider and MSO Portals

Proven Expertise And Capabilities In

Managing Cancer Care

Effective Integration Of Providers, Payers

And Specialty Pharmacy

16NCH_003_NCH Print Ad.indd 1 12/21/16 10:00 PM

42

Pioneers in patient relationship management for cancer care since 2008. navigatingcancer.com

A patient first approach:Is your practice prepared for the future of cancer care?

We can help.

We work hand-in-hand with healthcare professionals to discover real opportunities for the improvement of individual cancer programs. Our portfolio of services and products offers the resources and expertise to achieve the best patient experience and outcomes—while strengthening your financial performance.

Value-Based Strategic Planning A Roadmap to the Future of Care

Physician Engagement & Alignment Laying the Foundation of Integrated Care

Clinical Care Design Creating a Patient-Centric Experience

ONC iQTM Business Intelligence A Digital Business Analytics Tool for Oncology Executives

Together, we can transform the delivery of cancer care.

We work hand-in-hand with healthcare professionals to discover real opportunities for the improvement of individual cancer programs. Our portfolio of services and products offers the resources and expertise to achieve the best patient experience and outcomes—while strengthening your financial performance.

Contact us to learn more about how we can help you build meaningful and sustainable solutions.

Call us at 404.836.2000 or [email protected]

oncologysolutions.com

Value-Based Strategic Planning A Roadmap to the Future of Care

Physician Engagement & Alignment Laying the Foundation of Integrated Care

Clinical Care Design Creating a Patient-Centric Experience

ONC iQ Business Intelligence A Digital Business Analytics Tool for Oncology Executives

43

Lighting the way to better cancer care.™

This study uses an Institutional Review Board approved protocol. ©2016 Animated Dynamics, Inc. 12/2016

800-963-3313 • www.AniDyn.com

Time lapse of tissue response

ADI’s innovative 4D technology (BioDynamic Imaging) uses light and doppler to optically measure the effects of chemotherapy agents on ex vivo cancer tissue prior to treating the patient.

Study sites are currently being considered for breast and badder cancer trails. Call 1-800-963-3313, ext. 701 to become a study site.

See the Light in New 4D Technology

Advanced solutions.Maximum business intelligence.

© 2016 Cardinal Health. All Rights Reserved. CARDINAL HEALTH, the Cardinal Health LOGO, ESSENTIAL TO CARE and VITALSOURCE are trademarks or registered trademarks of Cardinal Health. All other marks are the property of their respective owners. Lit. No. 1SS16-613610 (12/2016)

New challenges require new solutions. VitalSource™ GPO delivers a comprehensive suite of group purchasing contracts and innovative business solutions for oncology — from inventory and financial management tools, to practice analytics and in-office dispensing — tailored to meet the needs of your patients and your practice.

Cardinal Health Specialty Solutions

See how we can create opportunities for you:Email: GMB-VitalSource Visit: cardinalhealth.com/vitalsourcegpo

It’s all in the deliveryCaring for cancer differently...

Taiho Oncology, Inc., is focused on bringing novel technology to cornerstone chemotherapies for a wide range of tumor types, including a variety of solid tumors. By developing oral oncolytic therapies, we are aspiring to deliver more meaningful moments to patients and to redefine the way the world treats cancer.

To learn more, please visit www.TaihoOncology.com.

© TAIHO ONCOLOGY, INC.03/2016 All rights reserved. TOI-PM-US-0076

Making the human connection

THIS ADVERTISEMENT PREPARED BY NeONClient: TAIHOProduct: TAIHO Job#: 10685774Job Name: Half Page – Journal AdAd Code: TOI-PM-US-0076

Publications:Colors: 4CSizes: Bleed: NONE

Trim: NONE Live: 8" W x 5" H

10685774 UPDATED CORP AD HALF PAGE AD

S:8”S:5”

10685774_Taiho_Corp_8x5_AD_FR1.indd 1 12/22/16 12:21 PM

44

IMPROVING THE BUSINESS OF ONCOLOGY

THROUGH A DATA-DRIVEN APPROACH

PHYSICIAN relationship management

BUSINESS intelligence

PATIENT marketing

Visit our booth to learn more & a chance to win big!

marketware.com

45

www.oncologymgmt.com - [email protected] - (610) 597-9799

• Hospital/Physician Integration

• Implementation and Interim Leadership

• Revenue Cycle Reviews

• Strategic Planning

• Financial and Market Analyses

• Operational Assessments

• New Center Development

• Performance and Financial Benchmarking

For more than 15 years, Oncology Management Consulting Group has provided the finest professional consulting services to oncology providersacross the US. With solutions tailored toeach client’s very precise needs,OMC Group offers the leadership, vision,and collaboration that oncologyorganizations need to adapt to and tosucceed in the rapidly changinghealthcare industry. We invite you tocall us at 610-597-9799 to discussthe possibilities!

OMC Group… Proud Sponsor of the2017 Cancer Center Business Summit.

•

•

•

PHC HAS THE EXPERTISE YOU NEED TO:

WE CAN HELP YOU MAKE THE RIGHT MOVES This kind of oncology expertise comes along

once in a blue moon

Cancer Program Planning & DevelopmentClinical Program Development | Operational AssessmentsBusiness & Compensation Valuation | Data Analytics 340B Assessment | Hospital-Physician Alignment StrategiesCoding, Billing & Medical Necessity AnalysesCancer Facility Planning | IT Risk ManagementAccreditation & Grants Management

PYA can help at every phase

| Oncology Facilities Planning

800.270.9629 | www.pyapc.comATLANTA | KANSAS CITY | KNOXVILLE | NASHVILLE | TAMPA

View Our Oncology Services at www.pyapc.com/oncology

DELIVERING CUSTOMIZED CONSULTING SOLUTIONS

CALL US: (301) 424-6000 | WWW.ONCOLOGYRESOURCE.COM 104 SOUTH WASHINGTON STREET | ROCKVILLE, MD 20850

SUCCESSFULLY NAVIGATING CHANGE WITH THE

ONCOLOGY COMMUNITY FOR 27 YEARS ∞∞∞∞

SUPPORTING YOUR ORGANIZATION’S PURSUIT OF EXCELLENCE AND VALUE IN

ONCOLOGY CARE DELIVERY ∞∞∞∞

CONTACT US TO DISCUSS CONSULTING

ASSISTANCE CUSTOMIZED FOR YOUR PLANNING NEEDS

46

Since 2004, Radiation Business Solutions has helped radiation practices to build more value. We provide new cancer center development services, total revenue cycle solutions, payer strategies, and practice consulting services to freestanding and hospital-based cancer centers across the country.

Find out how Radiation Business Solutions can help your revenue cycle to run more smoothly – and allow you to focus on patient care.

Call us today: 615.746.4711

Business, Run Better.

1044 Jackson Felts Road | Joelton, TN 37080 www.RadiationBusiness.com To speak to one of our experts, call 512.583.2000.

Or visit our website at www.revenuecycleinc.com

Medical and Radiation Oncology Services- Financial Planning and Analysis- Business and Clinical Operations- Revenue Cycle Assessment- Revenue Recovery- Billing, Coding and Compliance Reviews- Revenue Management Solutions- Revenue Management Solutions

As a recognized leader in the business of medical and radiation oncology,Revenue Cycle Inc. is a full service oncology-specific consulting firm. Our team delivers customized, leading-edge strategies and services foryour cancer facility.

Your Expert Oncology Resource

The know error® system is the only solution to mitigate the implications of undetected biopsy switching errors and tissue contamination.

The person in personalized medicine.®

To learn more visit www.knowerror.com or call Client Services 888-924-6779, option 2.

know error® is a registered trademark of Strand Diagnostics, LLC. © 2016 12/2016

Rise to a superior level of safety standards and differentiate your practice by utilizing the patented know error® system for biopsy patients. It is known that up to 3% of breast and prostate biopsy patients suffer a specimen provenance error which can result in patient harm.Know Error’s DNA Specimen Provenance Assay (DSPA) can rule out specimen contamination and switching errors before adverse patient outcomes.

The Standard Practice just got BetterSuperior

www.rxvantage.com/practice-solutions

RxVantage.com saves valuable time by helping you and your staff manage rep visits to your practice. Reps book appointments online instead of in your waiting room. Set custom visitation rules to govern who can book and how often, while RxVantage automatically enforces your rules for you.

Quick & easy online setup, no cost to use.Fully customizable rules & preferences.Access PAPs & FinancialAid forms all in one place.Automatic reminders & confirmations.No more paper calendars and lost business cards.Sunshine Act tracking &reporting.

47

ARIA RESORT, LEVEL 3, IRONWOOD BALLROOM

RESTROOMSRESTROOMS

S TAG E

1

2

3

4

1 2 3

4 5

6 7 8

3A 3B

1

2

5

3

4

6

7

13

1211

8

910

COTTONWOODBOARDROOM

SENNABOARDROOM

GREENROOM

IRONWOOD BALLROOM J U NIPER BALLROOM

S TARVINE M EETING ROOMS

LE

VE

L 3

JOIN US TOTRANSFORM HEALTHCARE

One-year Executive MBA for Healthcare Leadership

Healthcare Executive Programsand Custom Solutions

Come see us at the Big OrangeUniversity of Tennessee booth

to get started.

©2014 Cephalon, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd. All rights reserved. ONC-40466 April 2014. Printed in USA.

Joan is more than just a patient going through

We see so much more than just cancer

Joan is already busy enough with hockey practices, dance recitals, and science fair supply shopping. Now she’s making room on the kitchen calendar for Q3W therapy sessions.

People like Joan are at the heart of what drives Teva Oncology. With over 100 years of global pharmaceutical expertise, our mission is to develop and deliver solutions that advance cancer care and improve the lives of people affected by cancer.

We treat the person, not just the cancer

CHEMOTHERAPY


NOTES

www.CancerBusinessSummit.com48


NOTES


THE 2017 CANCER CENTER BUSINESS SUMMIT IS PRODUCED BY THE FOLLOWING HOST ORGANIZATIONS

Foley & Lardner LLP is a national law firm providing comprehensive legal services for innovative enterprises in the health care, pharmaceutical, biotechnology and biomedical sectors. Our health care attorneys provide counsel on financial transactions, mergers, acquisitions, affiliations, joint ventures, regulatory and government compliance, and business operations. With offices through-out the United States and the backing of Foley’s Health Care Industry Team, named “Law Firm of the Year — Health Care Law” for three years in a row by U.S. News – Best Lawyers®. Foley is well-positioned to serve the wide-ranging needs of cancer care providers and other health care organizations across the country.

NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth’s unique systems-based approach to personalized healthcare applies novel diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with large-scale, real-time biometric signal and phenotypic data to track patient outcomes and deliver precision medicine. For nearly a decade, NantHealth has developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets billions of molecular, clinical, operational and financial data points derived from novel and traditional sources, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time. For more informa-tion please visit www.nanthealth.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.

Cancer Center Business Development Group provides business and financial advisory expertise to stakeholders in the delivery of cancer care. Practice partnering strategies. Planning, development and operational transformation of comprehensive service lines/cancer centers. Design and implementation of innovative cancer care delivery models, such as the oncology medical home and oncology specialist networks. Initiatives in value-based alternative payment models in oncology, including the Oncology Care Model (OCM) and commercial bundled pricing methodologies. www.ccbdgroup.com.

The Association of Community Cancer Centers (ACCC) promotes the entire continuum of quality cancer care for our patients and our communities. Since 1974, ACCC has been helping oncology professionals adapt to the complex changes of delivering quality cancer care. ACCC members rely on the Association to bring them information on cancer program management, reimbursement issues, legislative and regulatory changes at the state and national levels, community cancer program standards, NCI-funded community clinical research, hospital alliances and physician relationships, and more. More than 23,000 cancer care professionals from over 2,500 hospitals and practices nationwide are affiliated with ACCC. It is estimated that 65 percent of the nation's cancer patients are treated by a member of ACCC.

www.CancerBusinessSummit.com50


SAVE THE DATEJoin Us for the

2018 Cancer Center Business Summit

March 14-16Washington, D.C.

www.CancerBusinessSummit.com 52www.CancerBusinessSummit.com

Transforming the Business of Oncology through … the 2017 Summit is Transforming the Business of...

Documents

Transcript of Transforming the Business of Oncology through … the 2017 Summit is Transforming the Business of...